Literature DB >> 18077096

Parascaris equorum in foals and in their environment on a Swedish stud farm, with notes on treatment failure of ivermectin.

K Lindgren1, O Ljungvall, O Nilsson, B-L Ljungström, C Lindahl, J Höglund.   

Abstract

Environmental contamination and the egg excretion pattern of the ascarid Parascaris equorum (Nematoda) was investigated in relation to anthelmintic treatment on a Swedish stud farm. Faecal samples from 15 foals, dewormed every 8th-week with a paste formulation of ivermectin at the standard dose rate of 0.2 mg/kg bodyweight, were collected at five sampling occasions between August and November 2006. In addition, soil samples were obtained from four paddocks used by these foals in November 2006. The number of eggs per gram (epg) was counted in both faeces and soil. Egg excretion started when the foals were 3-4 months, and reached the highest levels when they were approximately 5-month-old, and was then followed by a decline. Egg excretion seemed to be unaffected by ivermectin despite these foals were dewormed at regular intervals. In four out of five foals examined 10 days after treatment, epg actually increased. In contrast, when either fenbendazol or pyrantel embonate were used instead of ivermectin, treatments were effective. The number of eggs in soil was significantly higher in the permanent paddock compared to in the temporarily used soil paddock and in the summer paddocks.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077096     DOI: 10.1016/j.vetpar.2007.10.014

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  9 in total

1.  Efficacy of levamisole and ivermectin in the control of bovine parasitic gastroenteritis in the sub-humid savanna zone of southeastern Nigeria.

Authors:  I K Idika; E A Okonkwo; D N Onah; I O Ezeh; C N Iheagwam; C O Nwosu
Journal:  Parasitol Res       Date:  2012-07-04       Impact factor: 2.289

2.  Restrictions of anthelmintic usage: perspectives and potential consequences.

Authors:  Martin K Nielsen
Journal:  Parasit Vectors       Date:  2009-09-25       Impact factor: 3.876

3.  Anthelmintic efficacy on Parascaris equorum in foals on Swedish studs.

Authors:  Eva Osterman Lind; Dan Christensson
Journal:  Acta Vet Scand       Date:  2009-11-22       Impact factor: 1.695

4.  Viability of Rhodococcus equi and Parascaris equorum eggs exposed to high temperatures.

Authors:  Laurent Hébert; Julien Cauchard; Pauline Doligez; Lola Quitard; Claire Laugier; Sandrine Petry
Journal:  Curr Microbiol       Date:  2009-09-01       Impact factor: 2.188

5.  Exploring the β-tubulin gene family in a benzimidazole-resistant Parascaris univalens population.

Authors:  Frida Martin; Peter Halvarsson; Nicolas Delhomme; Johan Höglund; Eva Tydén
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2021-08-26       Impact factor: 4.077

6.  Ivermectin-induced gene expression changes in adult Parascaris univalens and Caenorhabditis elegans: a comparative approach to study anthelminthic metabolism and resistance in vitro.

Authors:  Faruk Dube; Andrea Hinas; Shweta Roy; Frida Martin; Magnus Åbrink; Staffan Svärd; Eva Tydén
Journal:  Parasit Vectors       Date:  2022-05-05       Impact factor: 4.047

Review 7.  The equine ascarids: resuscitating historic model organisms for modern purposes.

Authors:  Jennifer L Cain; Martin K Nielsen
Journal:  Parasitol Res       Date:  2022-08-20       Impact factor: 2.383

8.  Deep amplicon sequencing of preselected isolates of Parascaris equorum in β-tubulin codons associated with benzimidazole resistance in other nematodes.

Authors:  Eva Tydén; Johan Dahlberg; Olof Karlberg; Johan Höglund
Journal:  Parasit Vectors       Date:  2014-08-29       Impact factor: 3.876

9.  Lighten up the dark: metazoan parasites as indicators for the ecology of Antarctic crocodile icefish (Channichthyidae) from the north-west Antarctic Peninsula.

Authors:  Thomas Kuhn; Vera M A Zizka; Julian Münster; Regina Klapper; Simonetta Mattiucci; Judith Kochmann; Sven Klimpel
Journal:  PeerJ       Date:  2018-05-11       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.